Parent Stress in a Randomized Clinical Trial of Atomoxetine and Parent Training for Children with Autism Spectrum Disorder
Luc Lecavalier, Xueliang Pan, Tristram Smith, Benjamin L Handen, L Eugene Arnold, Laura Silverman, Rameshwari V Tumuluru, Jill Hollway, Michael G Aman, Luc Lecavalier, Xueliang Pan, Tristram Smith, Benjamin L Handen, L Eugene Arnold, Laura Silverman, Rameshwari V Tumuluru, Jill Hollway, Michael G Aman
Abstract
We previously reported a 2 × 2 randomized clinical trial of atomoxetine (ATX) and parent training (PT) for attention deficit hyperactivity disorder (ADHD) symptoms and behavioral noncompliance in 128 children with autism spectrum disorder, ages 5-14 years. Children were randomized to one of four conditions: ATX alone, placebo alone, ATX + PT, or PT + placebo. Both ATX and PT improved some indices of ADHD and behavioral compliance. In this report, we describe parent stress over time and across conditions. All four treatments improved parent self-rated stress from baseline to week 10. However, there were no statistically significant differences between treatment groups. Significantly more improvement in parent stress scores was observed for clinical responders than non-responders. ClinicalTrials.gov Title: Atomoxetine, Placebo and Parent Management Training in Autism (Strattera) ClinicalTrials.gov Identifier: NCT00844753.
Keywords: Atomoxetine; Attention deficit hyperactivity disorder; Autism spectrum disorder; Parent stress; Parent training.
Source: PubMed